KR102665887B1 - Ampa 수용체 강화제 - Google Patents

Ampa 수용체 강화제 Download PDF

Info

Publication number
KR102665887B1
KR102665887B1 KR1020197024520A KR20197024520A KR102665887B1 KR 102665887 B1 KR102665887 B1 KR 102665887B1 KR 1020197024520 A KR1020197024520 A KR 1020197024520A KR 20197024520 A KR20197024520 A KR 20197024520A KR 102665887 B1 KR102665887 B1 KR 102665887B1
Authority
KR
South Korea
Prior art keywords
compound
disorder
compounds
treatment
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197024520A
Other languages
English (en)
Korean (ko)
Other versions
KR20190117549A (ko
Inventor
사이먼 와드
폴 베스윅
루이스 페니콧
트리스탄 레윌런
Original Assignee
유니버시티 칼리지 카디프 컨설턴츠 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 칼리지 카디프 컨설턴츠 리미티드 filed Critical 유니버시티 칼리지 카디프 컨설턴츠 리미티드
Publication of KR20190117549A publication Critical patent/KR20190117549A/ko
Application granted granted Critical
Publication of KR102665887B1 publication Critical patent/KR102665887B1/ko
Assigned to 드레이그 테라퓨틱스 엘티디 reassignment 드레이그 테라퓨틱스 엘티디 권리의 전부이전등록 Assignors: 유니버시티 칼리지 카디프 컨설턴츠 리미티드
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
KR1020197024520A 2017-02-10 2018-02-09 Ampa 수용체 강화제 Active KR102665887B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1702221.1A GB201702221D0 (en) 2017-02-10 2017-02-10 Compounds
GB1702221.1 2017-02-10
PCT/GB2018/050370 WO2018146486A1 (en) 2017-02-10 2018-02-09 Ampa receptor potentiators

Publications (2)

Publication Number Publication Date
KR20190117549A KR20190117549A (ko) 2019-10-16
KR102665887B1 true KR102665887B1 (ko) 2024-05-10

Family

ID=58462168

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197024520A Active KR102665887B1 (ko) 2017-02-10 2018-02-09 Ampa 수용체 강화제

Country Status (12)

Country Link
US (1) US11186567B2 (https=)
EP (1) EP3580213B1 (https=)
JP (1) JP7014808B2 (https=)
KR (1) KR102665887B1 (https=)
CN (1) CN110520418B (https=)
AU (1) AU2018218307C1 (https=)
ES (1) ES2974824T3 (https=)
GB (1) GB201702221D0 (https=)
MX (1) MX2019009537A (https=)
NZ (1) NZ755747A (https=)
RU (1) RU2019126574A (https=)
WO (1) WO2018146486A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds
CN121487750A (zh) * 2023-06-15 2026-02-06 上海魁特迪生物科技有限公司 Dir结合剂及其用途
CN121652294A (zh) * 2026-02-06 2026-03-13 首都医科大学宣武医院 一种用于检测抗ampar1抗体的融合蛋白及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008148836A1 (en) 2007-06-08 2008-12-11 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
JP2009541404A (ja) 2006-07-04 2009-11-26 ナームローゼ・フエンノートチヤツプ・オルガノン Ａｍｐａ増強剤としてのピラゾールアルカンアミド置換チオフェン
WO2009147167A1 (en) 2008-06-06 2009-12-10 N.V. Organon Indane derivatives as ampa receptor modulators
JP2011503139A (ja) 2007-11-13 2011-01-27 ナームローゼ・フエンノートチヤツプ・オルガノン 複素環式誘導体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW575561B (en) 1999-03-25 2004-02-11 Hoffmann La Roche 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
IL152848A0 (en) 2000-06-12 2003-06-24 Eisai Co Ltd 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof
AU2003302027A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
JP5289043B2 (ja) 2005-04-12 2013-09-11 ヴィコール・ファルマ・アーベー 新規な三環系アンジオテンシンｉｉアゴニスト
CA2646585A1 (en) 2006-03-20 2007-09-27 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
EP2049475B1 (en) 2006-04-24 2012-02-01 Eli Lilly & Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
DE602007013450D1 (de) * 2006-11-03 2011-05-05 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
GB0711089D0 (en) * 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
EP2183228B1 (en) 2007-07-26 2014-08-20 Vitae Pharmaceuticals, Inc. CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1
KR20100063087A (ko) 2007-09-20 2010-06-10 코텍스 파마슈티칼스, 인크. 글루타메이트 시냅스 반응 향상을 위한 3-치환된 1,2,3-트리아진-4-온 및 3-치환된 1,3-피리미디논
GB0721094D0 (en) 2007-10-26 2007-12-05 Glaxo Group Ltd Compounds
AR071236A1 (es) 2008-05-01 2010-06-02 Vitae Pharmaceuticals Inc Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
TW201031649A (en) 2008-12-02 2010-09-01 Organon Nv 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives
AP3066A (en) 2009-06-26 2014-12-31 Pfizer Heterocyclic sulfonamides, uses and pharmaceuticalcompositions thereof
WO2011132051A2 (en) 2010-04-19 2011-10-27 Glenmark Pharmaceuticals S.A. Tricycle compounds as phosphodiesterase-10 inhibitors
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009541404A (ja) 2006-07-04 2009-11-26 ナームローゼ・フエンノートチヤツプ・オルガノン Ａｍｐａ増強剤としてのピラゾールアルカンアミド置換チオフェン
WO2008148836A1 (en) 2007-06-08 2008-12-11 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
JP2011503139A (ja) 2007-11-13 2011-01-27 ナームローゼ・フエンノートチヤツプ・オルガノン 複素環式誘導体
WO2009147167A1 (en) 2008-06-06 2009-12-10 N.V. Organon Indane derivatives as ampa receptor modulators
JP2011523656A (ja) 2008-06-06 2011-08-18 ナームローゼ・フエンノートチヤツプ・オルガノン Ａｍｐａ受容体モジュレーターとしてのインダン誘導体

Also Published As

Publication number Publication date
EP3580213A1 (en) 2019-12-18
RU2019126574A3 (https=) 2021-03-29
JP7014808B2 (ja) 2022-02-01
KR20190117549A (ko) 2019-10-16
GB201702221D0 (en) 2017-03-29
MX2019009537A (es) 2019-10-04
AU2018218307C1 (en) 2022-06-23
RU2019126574A (ru) 2021-03-10
WO2018146486A1 (en) 2018-08-16
ES2974824T3 (es) 2024-07-01
CA3051647A1 (en) 2018-08-16
EP3580213C0 (en) 2024-03-27
AU2018218307A1 (en) 2019-08-15
EP3580213B1 (en) 2024-03-27
US11186567B2 (en) 2021-11-30
BR112019016603A2 (pt) 2020-03-31
CN110520418A (zh) 2019-11-29
NZ755747A (en) 2022-02-25
AU2018218307B2 (en) 2022-02-24
JP2020507592A (ja) 2020-03-12
CN110520418B (zh) 2022-08-16
US20210139463A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
KR102665887B1 (ko) Ampa 수용체 강화제
JP2007512251A (ja) ４−フェニルピペリジンスルホニルグリシン輸送体インヒビター
US20250375432A1 (en) Compounds that modulates ampa receptor function
WO2004110986A1 (ja) ベンズアミド誘導体又はその塩
CA2951497A1 (en) Imidazopyridazine derivatives as modulators of the gabaa receptor activity
JP2013505217A (ja) 置換ｎ−フェニル−１−（４−ピリジニル）−１ｈ−ピラゾル−３−アミン類
KR20130122531A (ko) Ｍｇｌｕｒ５ 양성 알로스테릭 조절물로서 치환된 ６­메틸니코틴아미드
TW202204343A (zh) 經取代之３－苯氧基氮雜環丁烷－１－基－吡
CA3051647C (en) Ampa receptor potentiators
BR112019016603B1 (pt) Composto, uso deste e uma formulação farmacéutica
HK40044378A (en) Compounds that modulates ampa receptor function
HK40044378B (en) Compounds that modulates ampa receptor function
CN101084215B (zh) 作为glyt1抑制剂的哌啶和氮杂环丁烷衍生物
TW201217336A (en) Chemical compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R14-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)